Receive our newsletter – data, insights and analysis delivered to you
  1. Deals Analysis
June 17, 2021

Medical Devices industry cross border deals total $3.5bn globally in May 2021

Total medical devices industry cross border deals worth $3.5bn were announced globally for May 2021, with the $830m private equity deal with Caris Life Sciences being the sector’s biggest investment, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

The value marked a decrease of 11.1% over the previous month of $3.97bn and a rise of 17.3% when compared with the last 12-month average of $3.01bn.

In terms of number of cross border deals, the sector saw a rise of 25.00% with 50 deals in May 2021 when compared to the last 12-month average of 40 deals.

In value terms, North America led the activity with cross border deals worth $2.22bn in May 2021.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

Medical Devices industry cross border deals in May 2021: Top deals

The top five cross border deals accounted for 62.1% of the overall value during May 2021.

The combined value of the top five cross border deals stood at $2.2bn, against the overall value of $3.5bn recorded for the month.

The top five medical devices industry cross border deals of May 2021 tracked by GlobalData were:

1) L.P, Canada Pension Plan Investment Board, ClearBridge Investments, Coatue Management, Columbia Threadneedle Investments, Eaton Vance, Fidelity Management & Research, First Light Asset Management, Highland Capital Management, Millennium Management, Orbimed Advisors, Pura Vida Investments, Rock Springs Capital Management, Silver Lake Management, T Rowe Price Associates, TPG Sixth Street Partners and Tudor Investment’s $830m private equity deal with Caris Life Sciences

2) The $540m venture financing of Noom by Novo Holdings, Oak HC/FT Partners, RRE Ventures, Samsung Ventures Investment, Sequoia Capital Operations, Silver Lake Management and Temasek Holdings (Private)

3) NeoGenomics’ $390m acquisition of Inivata

4) The $235m private equity deal of Cue Health by ACME Capital, CAVU Venture Partners, Decheng Capital, Johnson & Johnson Innovation – JJDC, Koch Strategic Platforms, MSD Capital and Perceptive Advisors

5) China Investment, EDBI, Novo Holdings and Vivo Capital’s venture financing deal with Esco Micro for $200m.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU